Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Income from Continuing Operations (2018 - 2025)

Eton Pharmaceuticals' Income from Continuing Operations history spans 7 years, with the latest figure at 1483000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 347.99% to 1483000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 4601000.0, a 20.35% decrease, with the full-year FY2025 number at 4601000.0, down 20.35% from a year prior.
  • Income from Continuing Operations hit 1483000.0 in Q4 2025 for Eton Pharmaceuticals, up from 1927000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ETON hit a ceiling of 5116000.0 in Q1 2021 and a floor of 6094000.0 in Q3 2021.
  • Historically, Income from Continuing Operations has averaged 1016800.0 across 5 years, with a median of 1565000.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: soared 392.62% in 2023 and later tumbled 407.34% in 2025.
  • Tracing ETON's Income from Continuing Operations over 5 years: stood at 1039000.0 in 2021, then fell by 12.22% to 912000.0 in 2022, then tumbled by 347.37% to 2256000.0 in 2023, then skyrocketed by 73.49% to 598000.0 in 2024, then surged by 347.99% to 1483000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ETON at 1483000.0 in Q4 2025, 1927000.0 in Q3 2025, and 2585000.0 in Q2 2025.